The Filing Desk

Co-Diagnostics vs Nexalin Technology

Co-Diagnostics CODX · Nexalin Technology NXL · Health Care Equipment

Co-Diagnostics reported revenue of $1 million in fiscal 2025, 2.0 times Nexalin Technology's $0 million in fiscal 2025. Co-Diagnostics' revenue fell 84.1% in its latest year, and Nexalin Technology's grew 78.8%. Co-Diagnostics had an operating margin of -8058.8%, against -2781.7% at Nexalin Technology.

Side by side

Co-DiagnosticsNexalin Technology
Latest fiscal yearFY2025, Dec 31, 2025FY2025, Dec 31, 2025
Revenue$1M$0M
Revenue growth−84.1%78.8%
Revenue growth a year, last 5 years−61.9%—
Gross margin64.3%79.7%
Operating margin−8,058.8%−2,781.7%
Net margin−7,533.6%−2,725.8%
Free cash flow−$30M—
Free cash flow margin−4,793.2%—
Return on capital——
Net debt to EBITDA——
Dividends and buybacks$0M$0M
Change in diluted share count31.6%77.9%
Last close$0.16$1.39
P/E at the last close——
Insider trades, last 12 months——
Piotroski F-score——
Amounts in each company's own currency, US$ unless marked (a foreign company may report in another), each company's latest fiscal year from its 10-K, or 20-F or 40-F for a foreign company. Growth rates compare with the year before; the five-year rate is the average a year. Free cash flow is cash from operations minus capital spending; return on capital is after-tax operating income over the money invested in the business; P/E is the last close over the latest earnings per share. Banks are measured differently (return on equity, efficiency ratio), so some rows apply to one company only.

Ten years

Revenue
US$ billions, fiscal years
Co-DiagnosticsNexalin Technology
Operating margin
Percent of revenue
Co-DiagnosticsNexalin Technology
Free cash flow
US$ billions. Cash from operations minus capital expenditure.
Co-DiagnosticsNexalin Technology

Start a new comparison

Source: the companies' Form 10-K filings, from SEC EDGAR, and the last close. For information only, not investment advice: the figures describe results, not which company is the better investment. The Filing Desk is not affiliated with either company. Full figures on the Co-Diagnostics and Nexalin Technology pages.